Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.
Drugmakers can now call on a host of RNA therapeutic modalities, but small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs still garner the highest upfront payments. Oligo therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results